• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/14/24 8:06:42 AM ET
    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ABOS alert in real time by email

    Gainers

    • CareCloud (NASDAQ:CCLDO) stock moved upwards by 46.1% to $15.5 during Tuesday's pre-market session.
    • Syra Health (NASDAQ:SYRA) shares increased by 33.08% to $1.77. The market value of their outstanding shares is at $11.6 million. As per the press release, Q1 earnings came out 3 days ago.
    • Vaxart (NASDAQ:VXRT) shares moved upwards by 20.71% to $0.99. The company's market cap stands at $175.0 million. As per the news, the Q1 earnings report came out yesterday.
    • Sharps Technology (NASDAQ:STSS) shares rose 15.72% to $0.26. The company's market cap stands at $4.0 million.
    • Harrow (NASDAQ:HROW) shares rose 12.84% to $13.62. The company's market cap stands at $481.8 million. As per the news, the Q1 earnings report came out yesterday.
    • Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 12.38% to $3.78. The company's market cap stands at $226.8 million. As per the press release, Q1 earnings came out today.

    Losers

    • Scorpius Holdings (AMEX:SCPX) stock declined by 56.5% to $0.08 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
    • Augmedix (NASDAQ:AUGX) stock declined by 37.18% to $1.47. The market value of their outstanding shares is at $71.9 million. As per the press release, Q1 earnings came out yesterday.
    • Akoya Biosciences (NASDAQ:AKYA) stock declined by 23.55% to $3.15. The market value of their outstanding shares is at $155.5 million. As per the press release, Q1 earnings came out yesterday.
    • Inotiv (NASDAQ:NOTV) stock declined by 18.47% to $3.4. The market value of their outstanding shares is at $87.6 million.
    • Inspire Veterinary (NASDAQ:IVP) stock decreased by 14.56% to $2.76. The company's market cap stands at $2.4 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares decreased by 14.22% to $0.33. The company's market cap stands at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $AKYA
    $AUGX
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    Harrow Inc.
    $HROW
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    Acumen Pharmaceuticals Inc.
    $ABOS
    6/17/2025$4.00Buy
    Citigroup
    Harrow Inc.
    $HROW
    6/12/2025$62.00Buy
    BTIG Research
    Harrow Inc.
    $HROW
    6/10/2025Outperform
    William Blair
    Harrow Inc.
    $HROW
    2/6/2025$57.00Buy
    H.C. Wainwright
    Harrow Inc.
    $HROW
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    Akoya BioSciences Inc.
    $AKYA
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    Vaxart Inc
    $VXRT
    8/15/2024$4.00Outperform
    Oppenheimer
    More analyst ratings

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    SEC Filings

    View All

    Amendment: Scorpius Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation

    8-K/A - Scorpius Holdings, Inc. (0001476963) (Filer)

    3/10/26 4:15:26 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/10/26 8:26:19 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inotiv Inc. filed SEC Form 8-K: Other Events

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/10/26 8:13:31 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Elaine J bought $15,921 worth of shares (40,000 units at $0.40), increasing direct ownership by 71% to 96,566 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    11/21/25 1:21:51 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

    NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid

    3/10/26 4:00:00 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 5, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that it will report financial results for its fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 12, 2026. The results will be shared in a press release before the market opens.About Syra HealthSyra Health is an integrated healthcare solutions company serving government and commercial healthca

    3/5/26 7:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

    NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner's 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be webcast live and can be found on the Company's website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (NASDAQ:HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front a

    3/4/26 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

    Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $4.00

    6/17/25 7:48:19 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Acumen Pharmaceuticals Inc.

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    3/10/26 9:45:26 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Opaleye Management Inc. sold $7,846,426 worth of shares (198,572 units at $39.51) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    3/5/26 4:05:14 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer & Corp Sec Meisner Derek M exercised 9,406 shares at a strike of $1.85 and sold $28,311 worth of shares (9,406 units at $3.01) (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    3/3/26 9:42:29 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

    Believe Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform Reiterate Intent to Vote Against Reverse Stock Split at September 19th Special Meeting ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.6 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today issued a statement in response to the Company's app

    9/18/25 9:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ABOS
    $AKYA
    $AUGX
    $DRMA
    Financials

    Live finance-specific insights

    View All

    Vaxart to Host Upcoming Conference Calls

    Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul

    3/3/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

    NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on

    2/18/26 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care